Hologic, Inc. (NASDAQ:HOLX) CFO Karleen Marie Oberton sold 1,312 shares of Hologic stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $41.90, for a total value of $54,972.80. Following the transaction, the chief financial officer now directly owns 10,206 shares in the company, valued at approximately $427,631.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Karleen Marie Oberton also recently made the following trade(s):
- On Tuesday, November 6th, Karleen Marie Oberton sold 546 shares of Hologic stock. The shares were sold at an average price of $39.96, for a total value of $21,818.16.
Shares of NASDAQ HOLX traded down $0.68 during trading hours on Friday, hitting $41.78. The stock had a trading volume of 2,607,170 shares, compared to its average volume of 1,970,584. The stock has a market cap of $11.23 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.88 and a beta of 0.65. Hologic, Inc. has a 52 week low of $35.10 and a 52 week high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). The firm had revenue of $813.50 million during the quarter, compared to the consensus estimate of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 22.93%. The company’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.50 EPS. On average, analysts predict that Hologic, Inc. will post 2.4 EPS for the current year.
Several equities analysts have weighed in on HOLX shares. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a research note on Wednesday, August 1st. Needham & Company LLC lifted their target price on Hologic from $43.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. Deutsche Bank lifted their target price on Hologic from $42.00 to $45.00 and gave the company a “hold” rating in a research note on Wednesday, August 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Wednesday, August 1st. Finally, Bank of America lifted their target price on Hologic from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $44.41.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in shares of Hologic by 0.9% in the 3rd quarter. BlackRock Inc. now owns 18,773,720 shares of the medical equipment provider’s stock valued at $769,349,000 after buying an additional 164,937 shares in the last quarter. Parnassus Investments CA grew its stake in shares of Hologic by 3.4% in the 2nd quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after buying an additional 535,745 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Hologic by 5.1% in the 2nd quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after buying an additional 282,510 shares in the last quarter. FMR LLC grew its stake in shares of Hologic by 6.4% in the 3rd quarter. FMR LLC now owns 2,438,184 shares of the medical equipment provider’s stock valued at $99,916,000 after buying an additional 146,726 shares in the last quarter. Finally, Partner Fund Management L.P. grew its stake in shares of Hologic by 20.3% in the 2nd quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock valued at $75,235,000 after buying an additional 319,846 shares in the last quarter. 98.74% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/11/10/hologic-inc-holx-cfo-karleen-marie-oberton-sells-1312-shares.html.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Read More: Why do companies issue stock splits?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.